COSCIENS Biopharma 미래 성장

Future 기준 확인 0/6

현재 COSCIENS Biopharma 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	26.7%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%

Feb 02

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 COSCIENS Biopharma 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NasdaqCM:CSCI - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2024	5	-23	-27	-27	N/A
6/30/2024	5	-18	-19	-19	N/A
3/31/2024	4	-18	-19	-19	N/A
12/31/2023	4	-17	-17	-17	N/A
9/30/2023	6	-18	-8	-8	N/A
6/30/2023	8	-17	-9	-9	N/A
3/31/2023	7	-20	-13	-13	N/A
12/31/2022	6	-23	-14	-14	N/A
9/30/2022	4	-13	-13	-13	N/A
6/30/2022	3	-12	-10	-10	N/A
3/31/2022	5	-10	-9	-9	N/A
12/31/2021	5	-8	-9	-9	N/A
9/30/2021	7	-7	-4	-4	N/A
6/30/2021	6	-6	-4	-4	N/A
3/31/2021	4	-7	-3	-3	N/A
12/31/2020	4	-5	-4	-4	N/A
9/30/2020	1	-5	-10	-10	N/A
6/30/2020	1	-4	-10	-10	N/A
3/31/2020	2	0	-10	-10	N/A
12/31/2019	1	-6	-11	-11	N/A
9/30/2019	2	-10	-10	-10	N/A
6/30/2019	2	-12	-10	-10	N/A
3/31/2019	2	-15	-13	-13	N/A
12/31/2018	27	4	7	7	N/A
9/30/2018	26	9	5	5	N/A
6/30/2018	25	2	N/A	2	N/A
3/31/2018	25	2	N/A	1	N/A
12/31/2017	1	-17	N/A	-23	N/A
9/30/2017	1	-25	N/A	-27	N/A
6/30/2017	1	-21	N/A	-27	N/A
3/31/2017	1	-25	N/A	-27	N/A
12/31/2016	1	-25	N/A	-29	N/A
9/30/2016	1	-27	N/A	-29	N/A
6/30/2016	1	-36	N/A	-31	N/A
3/31/2016	1	-44	N/A	-33	N/A
12/31/2015	1	-50	N/A	-34	N/A
9/30/2015	0	-36	N/A	-34	N/A
6/30/2015	0	-32	N/A	-33	N/A
3/31/2015	0	-23	N/A	-32	N/A
12/31/2014	0	-17	N/A	-31	N/A
9/30/2014	N/A	-32	N/A	-19	N/A
6/30/2014	0	-28	N/A	-21	N/A
3/31/2014	0	-33	N/A	-24	N/A
12/31/2013	6	-27	N/A	-20	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CSCI 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: CSCI 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: CSCI 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: CSCI 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: CSCI 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CSCI 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

COSCIENS Biopharma 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target decreased to US$1.50

Recent updates

Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Second quarter 2024 earnings released: US$0.64 loss per share (vs US$2.07 loss in 2Q 2023)

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna slips ~10% after announcing date of reverse stock split

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$1.50

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Aeterna Zentaris names Michael Teifel as chief scientific officer

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: US$1.08

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: US$0.69

New 90-day high: US$0.51

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

New 90-day high: US$0.44

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: US$0.33

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

New 90-day low: US$0.38

First half earnings released

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견